Our ICM studies show that LUM/IVA combination therapy improves CFTR activity in F/F CF patients aged 2–11 years to levels comparable to the lower range of levels in patients with CF and CFTR variants with residual CFTR function (Hirtz et al., 2004). This evidence concerns the gene CFTR and cystic fibrosis.